Experienced in Telangiectasia

Dr. Jill Waibel

Dermatology
Miami Dermatology And Laster Institute
3683 S Miami Ave Ste 200, 
Miami, FL 
Offers Telehealth
Experienced in Telangiectasia
Miami Dermatology And Laster Institute
3683 S Miami Ave Ste 200, 
Miami, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jill Waibel is a Dermatologist in Miami, Florida. Dr. Waibel is rated as an Experienced provider by MediFind in the treatment of Telangiectasia. Her top areas of expertise are Hypomelanotic Disorder, Dyschromatosis Symmetrica Hereditaria, Dyschromatosis Universalis Hereditaria, and Griscelli Syndrome.

Her clinical research consists of co-authoring 61 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in OH
Hospital Affiliations
South Miami Hospital
Baptist Hospital Of Miami
Geisinger Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health New England
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Home State Health
  • EPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 29 Less Insurance Carriers -

Locations

Miami Dermatology and Laster Institute
3683 S Miami Ave Ste 200, Miami, FL 33133

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Prospective Blinded Within-Subject Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
A Prospective Blinded Within-Subject Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Device
Study Phase: Not Applicable
Phase 2a Prospective, Randomized, Double-blind, Intra-subject, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy of OLX10010 as an Adjunct Therapy to Reduce the Recurrence of Hypertrophic Scars After Scar Revision Surgery
Phase 2a Prospective, Randomized, Double-blind, Intra-subject, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy of OLX10010 as an Adjunct Therapy to Reduce the Recurrence of Hypertrophic Scars After Scar Revision Surgery
Enrollment Status: Completed
Publish Date: February 21, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 1
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: NKTR-358
Study Phase: Phase 1
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of LY3454738 in Adults With Chronic Spontaneous Urticaria Inadequately Controlled With H1-Antihistamines
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of LY3454738 in Adults With Chronic Spontaneous Urticaria Inadequately Controlled With H1-Antihistamines
Enrollment Status: Terminated
Publish Date: March 11, 2022
Intervention Type: Drug
Study Drug: LY3454738
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis: The ADmIRe Study
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis: The ADmIRe Study
Enrollment Status: Terminated
Publish Date: April 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
The CONFORM Study: A Multi-center Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring
The CONFORM Study: A Multi-center Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring
Enrollment Status: Completed
Publish Date: February 03, 2021
Intervention Type: Device
Study Phase: Not Applicable
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
The INFORM Study: A Multi-Center Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring With an Optimized Post-Procedure Treatment Plan
The INFORM Study: A Multi-Center Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring With an Optimized Post-Procedure Treatment Plan
Enrollment Status: Unknown
Publish Date: March 06, 2020
Intervention Type: Device
Study Phase: Not Applicable
View 13 Less Clinical Trials

59 Total Publications

Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
Journal: Lancet (London, England)
Published: July 08, 2025
View All 59 Publications
Similar Doctors
Distinguished in Telangiectasia
Dr. Deborah Saff
Dermatology
Distinguished in Telangiectasia
Dr. Deborah Saff
Dermatology

Office

230 George Bush Blvd, 
Delray Beach, FL 
 (56.2 miles away)
561-276-3111
Languages Spoken:
English
See accepted insurances

Deborah Saff is a Dermatologist in Delray Beach, Florida. Dr. Saff is rated as an Advanced provider by MediFind in the treatment of Telangiectasia. Her top areas of expertise are Spider Angioma, Telangiectasia, Contact Dermatitis, and Actinic Keratosis.

Distinguished in Telangiectasia
Dr. Steven Hacker
Dermatology
Distinguished in Telangiectasia
Dr. Steven Hacker
Dermatology

Office

230 George Bush Blvd, 
Delray Beach, FL 
 (56.2 miles away)
561-276-3111
Languages Spoken:
English
See accepted insurances

Steven Hacker is a Dermatologist in Delray Beach, Florida. Dr. Hacker is rated as a Distinguished provider by MediFind in the treatment of Telangiectasia. His top areas of expertise are Spider Angioma, Telangiectasia, Rosacea, and Purpura.

Advanced in Telangiectasia
Dr. Ivan Camacho
Dermatology
Advanced in Telangiectasia
Dr. Ivan Camacho
Dermatology

Dr Jane Asprinio O'Brien PA

1295 NW 14th St, 
Miami, FL 
 (9.7 miles away)
305-243-6704
Languages Spoken:
English
See accepted insurances

Ivan Camacho is a Dermatologist in Miami, Florida. Dr. Camacho is rated as a Distinguished provider by MediFind in the treatment of Telangiectasia. His top areas of expertise are Universal Acquired Melanosis, Liver Spots, Warts, and Actinic Keratosis.

VIEW MORE TELANGIECTASIA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Waibel's expertise for a condition
ConditionClose
    • Distinguished
    • Hypomelanotic Disorder
      Dr. Waibel is
      Distinguished
      . Learn about Hypomelanotic Disorder.
      See more Hypomelanotic Disorder experts
    • Advanced
    • Acne
      Dr. Waibel is
      Advanced
      . Learn about Acne.
      See more Acne experts
    • Actinic Keratosis
      Dr. Waibel is
      Advanced
      . Learn about Actinic Keratosis.
      See more Actinic Keratosis experts
    • Atopic Dermatitis
      Dr. Waibel is
      Advanced
      . Learn about Atopic Dermatitis.
      See more Atopic Dermatitis experts
    • Cutis Laxa
      Dr. Waibel is
      Advanced
      . Learn about Cutis Laxa.
      See more Cutis Laxa experts
    • Dyschromatosis Symmetrica Hereditaria
      Dr. Waibel is
      Advanced
      . Learn about Dyschromatosis Symmetrica Hereditaria.
      See more Dyschromatosis Symmetrica Hereditaria experts
    • Dyschromatosis Universalis Hereditaria
      Dr. Waibel is
      Advanced
      . Learn about Dyschromatosis Universalis Hereditaria.
      See more Dyschromatosis Universalis Hereditaria experts
    View All 11 Advanced Conditions
    • Experienced
    • Bullous Pemphigoid
      Dr. Waibel is
      Experienced
      . Learn about Bullous Pemphigoid.
      See more Bullous Pemphigoid experts
    • Cerebral Cavernous Malformation
      Dr. Waibel is
      Experienced
      . Learn about Cerebral Cavernous Malformation.
      See more Cerebral Cavernous Malformation experts
    • Cherry Angioma
      Dr. Waibel is
      Experienced
      . Learn about Cherry Angioma.
      See more Cherry Angioma experts
    • Chronic Spontaneous Urticaria (CSU)
      Dr. Waibel is
      Experienced
      . Learn about Chronic Spontaneous Urticaria (CSU).
      See more Chronic Spontaneous Urticaria (CSU) experts
    • Comedones
      Dr. Waibel is
      Experienced
      . Learn about Comedones.
      See more Comedones experts
    • Contact Dermatitis
      Dr. Waibel is
      Experienced
      . Learn about Contact Dermatitis.
      See more Contact Dermatitis experts
    View All 34 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.